1999, Taxus plantation
……
2001, company established
2007, GMP approved(natural Paclitaxel)
2009, changed to current name.
2011, sales volume more than RMB100million
2012, passed GMP re-inspection.
2014, IPO, received production license of Letrozole,Gefitinib and Erlotinib
2015, received Docetaxel GMP, received BE license of Imatinib,Erlotinib(API and tablet), passed US-FDA GMP inspection.
2016, received Paclitaxel GMP, received BE license of Letrzole(API and tablet)
2017, Hanxian site construction.
2018, passed EDQM on-site GMP inspection.
2021, Bendamustine HCL GMP approval
2022, Cofepris PIC/s GMP approval, 7 APIs GMP approval.
2023, 10 APIs GMP approval.
2024, USFDA on-site inspection
……
